Editas Medicine has been granted a patent for methods and compositions to enhance the compatibility of donor cells for transplantation. The invention involves modifying immunogenicity genes in cells, such as HLA genes, to reduce cell surface expression of specific proteins, making them suitable for transplantation. GlobalData’s report on Editas Medicine gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Editas Medicine Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Editas Medicine, CRISPR genome editing was a key innovation area identified from patents. Editas Medicine's grant share as of February 2024 was 16%. Grant share is based on the ratio of number of grants to total number of patents.

Allele-specific modification of hla genes for cell transplantation

Source: United States Patent and Trademark Office (USPTO). Credit: Editas Medicine Inc

A recently granted patent (Publication Number: US11911415B2) outlines a method for reducing the cell surface expression of a protein encoded by a specific allele of an endogenous human leukocyte antigen (HLA) gene in blood cells. The method involves contacting the blood cell with an allele-specific gRNA molecule and a Cas9 molecule, leading to a knock-out or knock-down of the expression of the targeted allele. This approach allows for the reduction of the cell surface expression of the protein encoded by the specific allele, potentially offering therapeutic benefits in various conditions.

Furthermore, the patent describes additional steps that can be included in the method, such as contacting the blood cell with a second gRNA molecule targeting other genes, selecting the gRNA molecule using a database schema, and transferring the modified blood cell to a second subject with a different haplotype at the endogenous HLA gene. The method also allows for the integration of a transgene into the genome of the blood cell, which could encode an HLA gene, a chemotherapy selection marker, a cell surface antigen, or a suicide gene. The use of an enzymatically inactive Cas9 (eiCas9) molecule fused to a transcriptional repressor or activator is also mentioned as part of the method. Overall, this patented method provides a detailed framework for manipulating gene expression in blood cells, potentially opening up new avenues for personalized medicine and therapeutic interventions.

To know more about GlobalData’s detailed insights on Editas Medicine, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies